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Tbjective: Statins are powerful lipid-lowering drugs that have been proved effective
n the prevention of coronary artery disease, clearly reducing the risk of mortality
nd cardiovascular events. Whether hyperlipidemic patients undergoing coronary
rtery bypass grafting profit from the lipid-lowering beneficial effects of statins is as
et uncertain. We sought to determine whether preoperative statin therapy may have
n effect on outcome among hyperlipidemic patients undergoing coronary artery
ypass grafting.
ethods: From January 2000 through March 2006, prospectively recorded clinical
ata from 3346 consecutive patients undergoing isolated first-time elective coronary
rtery bypass grafting were analyzed for major adverse cardiac events and all-cause
n-hospital mortality. Of these, 167 patients had preoperative statin-untreated hy-
erlipidemia (group 1), 2592 had statin-treated hyperlipidemia (group 2), and 587
ad statin-untreated normolipidemia (group 3).
esults: Risk-adjusted multivariate logistic regression analysis revealed statin-
reated hyperlipidemia (odds ratio, 0.42; 95% confidence interval, 0.26-0.69; P 
0007) and statin-untreated normolipidemia (odds ratio, 0.42; confidence interval,
.26-0.69; P .0007) to be independently associated with reduced in-hospital major
dverse cardiac events but not with in-hospital mortality. To further control for selection
ias, a computed propensity score matching based on 14 major preoperative risk factors
as performed. After propensity matching, conditional logistic regression analysis
onfirmed statin-treated hyperlipidemia and statin-untreated normolipidemia to be
trongly related to reduced in-hospital major adverse cardiac events (odds ratio, 0.41;
5% confidence interval, 0.24–0.71 [P  .0013] and odds ratio, 0.23; 95% confidence
nterval, 0.11–0.48 [P  .0001]) but not with in-hospital mortality (odds ratio, 1.18;
5% confidence interval, 0.36–3.87 [P  .79] and odds ratio, 1.10; 95% confidence
nterval, 0.32–4.41 [P  .80]) after coronary artery bypass grafting surgery.
onclusions: Hyperlipidemic, but not normolipidemic, patients have an increased
isk for in-hospital major adverse cardiac events and therefore clearly benefit from
reoperative statin therapy before coronary artery bypass grafting surgery.
yperlipidemia is known as one of the major risk factors associated with
vascular endothelial injury, causing atherosclerotic plaque formation and
coronary artery disease (CAD) that result in recurrent ischemic cardiovas-
ular events.1 Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reducta
tatins, are recognized as powerful lipid-lowering drugs that have been proved
ighly effective in primary and secondary prevention of CAD, decreasing low-
ensity lipoprotein cholesterol (LDL-C) levels and thereby reducing the risk of
ortality and cardiovascular adverse events in hyperlipidemic and normocholester-
he Journal of Thoracic and Cardiovascular Surgery ● Volume 134, Number 5 1143
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CDlemic patients.2 In terms of surgical intervention, preop-
tive statin therapy has recently been shown to reduce the
isk of early mortality in noncardiac3-5 and cardiac6-9 oper-
tions, suggesting early beneficial effects of statin treat-
ent, irrespective of hyperlipidemia. To further differenti-
te lipid-dependent early beneficial statin effects, we sought
o determine whether preoperative statin therapy might be
ssociated with a reduced risk of postoperative death or major
dverse cardiac events (MACEs) in patients with hyperlipid-
mia undergoing CABG and whether statin-untreated normo-
ipidemic patients might have in turn an increased risk for
ostoperative death and MACEs after CABG.
aterials and Methods
tudy Design
his study was a retrospective single-center cohort study including
346 consecutive patients who underwent first-time isolated elec-
ive CABG at the West German Heart Center Essen between
anuary 2000 and March 2006. Patients were included in and
lassified into one of 3 groups, depending on whether they had
tatin-untreated hyperlipidemia (group 1), statin-treated hyperlip-
demia (group 2), or statin-untreated normolipidemia (group 3)
efore CABG surgery. The most recent levels of total cholesterol,
DL-C, high-density lipoprotein cholesterol, and triglyceride in
erum within 1 month before surgical intervention were recorded.
yperlipidemia was defined as a serum total cholesterol level of
00 mg/dL or greater and/or a low-density lipoprotein level of 130
g/dL or greater and/or use of lipid-lowering statin therapy with a
istory of hyperlipidemia. Preoperative statin therapy consisted of
ne the following statins before CABG: pravastatin, simvastatin,
uvastatin, atorvastatin, cerivastatin, or lovastatin. Surgical revas-
ularization was routinely performed as previously described10 in
ll patients by using a median sternotomy, a standard CPB tech-
ique with ascending aortic and 2-stage venous cannulation, mild
ypothermia (32°C), and cold crystalloid cardioplegic arrest. Off-
ump coronary operations, emergency or urgent surgical intervention,
revious myocardial infarction (4 weeks) before CABG, reopera-
ive procedures, or concomitant operations were the exclusion criteria.
he institutional review board approved the study. All of the patients
ad previously granted permission for use of their medical records for
esearch purposes.
ata Collection
ata used in this analysis were retrieved from the West German
Abbreviations and Acronyms
CAD  coronary artery disease
CI  confidence interval
LCOS  low cardiac output syndrome
LDL-C low-density lipoprotein cholesterol
MACE major adverse cardiac event
PMI  perioperative myocardial infarction
OR  odds ratioeart Center cardiovascular surgical database. This database pro- a
144 The Journal of Thoracic and Cardiovascular Surgery ● Novpectively collects a comprehensive list of prespecified data points,
ith more than 1800 data items per patient for all of the consec-
tive patients undergoing CABG surgery at our institution, includ-
ng demographic, clinical, and outcome data. Within the database,
atients were coded as having statin-untreated hyperlipidemia,
tatin-treated hyperlipidemia, or statin-untreated normolipidemia.
utcome Measures
ll outcome measures used in this analysis were prespecified.
iven the subject nature of many clinical outcomes, we only
respecified all-cause in-hospital mortality after CABG as the
rimary study end point. The prespecified secondary end point was
he MACE rate, including sudden cardiac death, cardiac death, low
ardiac output syndrome (LCOS), and perioperative myocardial
nfarction (PMI), during the postoperative hospitalization period.
n independent review of the medical records of the patients who
ied after CABG operations was performed, and cardiac versus
oncardiac cause of death was adjudicated.
efinitions
n-hospital death was defined as death after CABG during the
ndex hospitalization. A PMI was considered to have occurred if
ne of the following diagnostic criteria were present: (1) a cardiac
roponin I level of greater than 10.5 ng/mL after CABG, as
reviously described11; (2) a creatine kinase–MB level 3 ti
reater than the upper normal level; (3) new persistent ST-segment
r T-wave changes (Minnesota code 4-1, 4-2, 5-1, 5-2, or 9-2); or
4) the development of new Q-waves (Minnesota code 1-1-1 to
-2-7). LCOS was supposed with a cardiac index of less than 2.0
· min1 · m2 or a systolic arterial pressure of less than 90 mm
g, despite high-dose inotropic support (intravenous dopamine, 8
g · kg1 · min1; dobutamine, 6 g · kg1 · min1; epineph-
ine, 0.1 g · kg1 · min1; or norepinephrine, 0.1 g · kg1 ·
in1). Death was considered cardiac if it was caused by PMI,
ignificant cardiac arrhythmias, or refractory LCOS. Sudden unex-
ected death occurring without another explanation was defined as
udden cardiac death.
tatistical Analysis
escriptive statistics are summarized for categoric variables as
requencies (percentages) and compared between groups by using
he Pearson 2 exact test. Continuous variables, expressed as
eans  standard deviations or as medians (interquartile ranges),
ere compared between groups by using the Kruskal–Wallis test.
hen a significant overall effect was detected, 2 group compari-
ons were performed with the Fisher exact test or the Mann–
hitney U test. Univariate and multivariate logistic regression
ere performed to identify preoperative independent predictors for
n-hospital mortality and MACEs. Those variables identified by
eans of univariate regression analysis with a P value of .05 or
ess for at least 1 study end point were added to the multivariate
ogistic regression model. Propensity score matching was per-
ormed to control for selection bias as a result of nonrandom
ssignment to the 3 groups.12 The propensity scores were calc-
ated separately, comparing group 1 versus group 2 and gro
ersus group 3. The following patient characteristics and major
reoperative risk factors were used to calculate propensity scores:
ge, sex, diabetes, hypertension, hyperlipidemia, left ventricular
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CDjection fraction, renal disease, previous myocardial infarction, left
ain disease, chronic obstructive pulmonary disease, peripheral
ascular disease, angina class III ot IV, aspirin and -blocker use,
nd the number of bypassed vessels. For both comparisons, pa-
ients with similar propensity scores were combined into 20
atched sets of equal size. Once patients were matched, condi-
ional logistic regression was used.13 All statistical analyses wer
erformed with the SAS System, version 8 (SAS Institute, Inc,
ary, NC).
esults
f the 3346 patients included in the present analysis, 167
yperlipidemic patients underwent CABG surgery without
reoperative statin therapy in group 1, whereas 2592 hyper-
ipidemic patients were taking statin therapy before surgical
ABLE 1. Preoperative patient characteristics
Group 1,
statin-untreated HLP
(n  167)
emographics
Age, y 65 9
Sex, female 37 (22)
isk factors and comorbidities
Diabetes mellitus 57 (34)
Hypertension 137 (82)
Hyperlipidemia 167 (100)
Obesity (BMI 30) 86 (52)
Smoking past 2 mo 32 (19)
Smoking past 1 y 61 (37)
COPD 24 (14)
Peripheral vascular disease 21 (13)
Renal disease (1.8 mg/dL) 21 (13)
ardiac history
Angina CCS III-IV 21 (13)
Previous MI (4 wk) 62 (37)
Previous PCI 28 (17)
LVEF, % 58 14
xtent of CAD
Triple-vessel disease 124 (74)
Left main disease 41 (25)
erum lipid levels
Total cholesterol, mg/dL 219 55
LDL-C, mg/dL 147 54
HDL-C, mg/dL 47 16
Triglyceride, mg/dL 190 89
dditional medication
Aspirin 92 (55)
-Blocker 121 (73)
ACE inhibitor 107 (65)
Nitrates 94 (56)
ata are presented as means standard deviation or number (percen
ulmonary disease; CCS, Canadian Cardiovascular Society; MI, myocard
jection fraction; LDL-C, low-density lipoprotein cholesterol; HDL-C, High-
ersus group 1. †P  .05 versus group 2.ntervention in group 2, and 587 patients were normolipi- l
The Journal of Thoracicemic without statins before surgical intervention in group 3.
reoperative characteristics of the patients are presented in
able 1. Patients were not significantly different accord
o their demographics, risk factors, and comorbidities, ex-
ept for age and a higher number of patients with hyperten-
ion in group 2 compared with those in groups 1 and 3.
atients did not differ according to their cardiac history and
heir extent of CAD, but statin-treated patients received
ignificantly more -blockers and tended to have more
spirin use compared with the statin-untreated hyperlipid-
mic and normolipidemic patients. Preoperative lipid levels
howed a significant difference in the total cholesterol level,
s well as the LDL-C levels, of statin-untreated group 1
ompared with statin-treated group 2, whereas high-density
roup 2,
-treated HLP
 2592)
P value
(group 1 vs group 2)
Group 3,
statin-untreated NLP
(n  587)
6  9 .001 67  9*†
07 (23) .78 128 (22)
57 (33) .80 191 (33)
78 (88) .04 423 (72)*†
92 (100) 1.00 0 (0)*†
91 (46) .17 253 (43)*
48 (17) .53 118 (20)
06 (35) .33 185 (32)*
58 (18) .30 110 (19)
07 (16) .32 72 (12)
32 (13) 1.00 65 (11)
78 (11) .44 72 (12)
35 (36) .80 214 (36)
80 (19) .68 91 (15)
7 14 .94 56  15*
47 (79) .60 449 (77)
68 (30) .19 167 (28)
3 64 .02 166 53*†
9 38 .01 103 25*†
6 15 .92 48  16
1 105 .77 162 81*†
02 (62) .09 311 (53)†
49 (79) .05 408 (70)†
03 (66) .17 316 (54)*
28 (55) .67 331 (56)
HLP, Hyperlipidemia; NLP, normolipidemia; COPD, chronic obstructive
arction; PCI, percutaneous coronary intervention; LVEF, Left ventricular
ty lipoprotein cholesterol; ACE, angiotensin-converting enzyme. *P  .05G
statin
(n
6
6
8
22
25
11
4
9
4
4
3
2
9
4
5
20
7
18
10
4
18
16
20
17
14
tage).
ial inf
densiipoprotein cholesterol and triglyceride levels did not
and Cardiovascular Surgery ● Volume 134, Number 5 1145
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CDhow any statistical difference between the groups. In-
raoperative results did not differ between the groups
Table 2). As a result, the usual postoperative outc
ata, such as length of ventilation time and intensive care
nit and hospital stay, did not differ between the groups.
he incidence of postoperative complications, such as
ostoperative stroke, supraventricular or ventricular ar-
hythmias, rethoracotomy, and other complications, were
lso not different (Table 2).
The postoperative incidence of primary and secondary
tudy end points are presented in Figures 1 and 2.
ncidence of all-cause in-hospital death did not differ be-
ween the groups. The in-hospital MACE rate, however,
howed a significant risk reduction in statin-treated hyper-
ipidemic patients compared with that in statin-untreated
ABLE 2. Intraoperative and postoperative characteristics
Group 1,
statin-untreated HLP
(n  167)
ntraoperative data
ACC time, min 70 24
CPB time, min 112 38
Reperfusion time, min 34 17
Grafts per patient, n 3.0 0.8
Mean graft flow, mL/min 54 32
ostoperative data
Ventilation time, h 8 (6–12)
IABP support 10 (6)
ICU stay, d 1 (1–3)
Hospital stay, d 9 (7–13)
ostoperative complications
Stroke 3 (2)
Renal failure (dialysis) 10 (3)
Supraventricular arrhythmia 15 (9)
Ventricular arrhythmia 36 (22)
ata are presented as means standard deviation, number (percentag
ormolipidemia; ACC, aortic crossclamp; CPB, cardiopulmonary bypass; IA146 The Journal of Thoracic and Cardiovascular Surgery ● Nove
yperlipidemic patients (from 12.6% to 5.7%, P  .001),
hich was almost comparable with that of statin-untreated
ormolipidemic patients, who had a MACE rate of 4.3%.
y analyzing all secondary end points, no statistical differ-
nce was found regarding the incidence of sudden cardiac
eath and cardiac death. The incidence of postoperative
COS was halved in the statin-treated group 2 but did not
each statistical significance (P  .07). Postoperative myo-
ardial infarction, however, was significantly less in group 2
5.1%) compared with that in group 1 (10.2%, P  .01) and
herewith reached almost the incidence of the normolipi-
emic group 3 patients.
A logistic regression analysis model was constructed to
valuate independent preoperative predictors of death, and
everal univariate factors were found to be predictive of
roup 2,
-treated HLP
 2592)
P value
(group 1 vs group 2)
Group 3,
statin-untreated NLP
(n  587)
2 24 .42 70 23
2 38 .11 111 37
5 19 .38 34 16
.0 0.8 .98 3.0 0.8
7 31 .13 54 36
8 (6–12) .34 8 (6–12)
0 (5) .45 22 (4)
1 (1–3) .87 1 (1–3)
8 (6–12) .14 8 (7–12)
4 (2) 1.00 9 (2)
2 (3) .13 14 (2)
1 (8) .55 46 (8)
6 (20) .69 112 (19)
median and interquartile range (15%-75%). HLP, Hyperlipidemia; NLP,
ntra-aortic balloon pump; ICU, intensive care unit.
Figure 1. Incidence of death and major adverse
cardiac events (MACE) during the hospital stay.
P values indicate overall significance between
groups 1 and 2 calculated by using the Pearson
2 exact test. OR, Odds ratio; CI, confidence
interval.G
statin
(n
7
11
3
3
5
12
5
9
20
52
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A
CDeath (Table 3). After risk adjustment, a multivariate lo
ic regression analysis revealed age, left ventricular func-
ion, peripheral vascular disease, and chronic obstructive
ulmonary disease to be independently related to in-hospital
eath, but none of the 3 groups were independent predictors
f death. As independent predictors for MACEs, the mul-
ivariate regression analysis revealed previous myocardial
nfarction, renal disease, and the number of grafted vessels
s highly related to MACEs, whereas preoperative statin
reatment of hyperlipidemic patients of group 2 and normo-
ipidemic patients of group 3 significantly reduced the risk
f in-hospital MACEs (Table 4).
In an attempt to further correct for and minimize selec-
ion bias, a computed propensity score matching of the
ABLE 3. Univariate and multivariate logistic regression a
Univariate an
Odds ratio (95% CI)
ge, y 1.06 (1.03–1.09)
ex, female 1.06 (0.65–1.74)
besity 1.10 (0.82–1.46)
eft main stem disease 1.11 (0.70–1.76)
VEF, % 0.98 (0.97–0.99)
eripheral vascular disease 2.70 (1.70–4.33)
OPD 2.82 (1.80–4.44)
iabetes mellitus 1.74 (1.13–2.69)
ypertension 1.49 (0.71–3.10)
ngina CCS III-IV 1.86 (1.09–3.17)
revious MI 1.32 (0.86–2.04)
enal disease 2.02 (1.21–3.36)
spirin 1.35 (0.84–2.16)
-Blockers 0.93 (0.68–1.27)
o. of bypassed vessels 1.22 (0.95–1.56)
roup 1: statin-untreated HLP Reference
roup 2: statin-treated HLP 1.10 (0.40–3.05)
roup 3: statin-untreated NLP 1.07 (0.35–3.27)
I, Confidence interval; LVEF, left ventricular ejection fraction; COPD, chron
yperlipidemia; NLP, normolipidemia.
The Journal of Thoracictudy groups based on 14 major preoperative risk factors
as performed, comparing group 1 versus group 2 and
roup 1 versus group 3. The c-index for the propensity
core model was 0.82, indicating that the model exhibits
ery good discrimination in separating dichotomies.
ven after propensity score matching, a conditional re-
ression analysis confirmed that there was no risk reduc-
ion for death, either with preoperative statins in hyperlip-
demic patients (odds ratio [OR], 1.18; 95% confidence
nterval [CI], 0.36–3.87; P  .79) or in statin-untreated
ormolipidemic patients (OR, 1.10; 95% CI, 0.32–4.41; P
.80), but as the main result, there was a significant risk
eduction for in-hospital MACEs for statin-treated hyper-
ipidemic patients (OR, 0.42; 95% CI, 0.24–0.71; P 
Figure 2. Incidence of secondary end points dur-
ing the hospital stay. P values indicate overall
significance between groups 1 and 2 calculated
by using the Pearson 2 exact test. OR, Odds
ratio; CI, confidence interval; LCOS, low cardiac
output syndrome; PMI, perioperative myocardial
infarction.
sis of variables associated with in-hospital death
Multivariate analysis
P value Odds ratio (95% CI) P value
.0001 1.06 (1.02–1.09) .0006
.82 — —
.51 — —
.67 — —
.01 0.99 (0.97–1.00) .04
.0001 1.91 (1.11–3.29) .02
.0001 2.24 (1.34–3.75) .002
.01 1.53 (0.94–2.50) .09
.29 — —
.02 1.24 (0.69–2.25) .47
.21 — —
.007 1.21 (0.67–2.21) .70
.64 — —
.64 — —
.12 — —
Reference Reference Reference
.86 — —
.91 — —
structive pulmonary disease; CCS, Canadian Cardiovascular Society; HLP,naly
alysis
ic oband Cardiovascular Surgery ● Volume 134, Number 5 1147
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A
CD0013), which was almost at the same level of statin-
ntreated normolipidemic patients (OR, 0.23; 95% CI,
.11–0.48; P  .0001).
iscussion
he present study is the first to clearly demonstrate that
reoperative statin therapy is significantly associated with a
isk reduction of in-hospital MACEs, particularly nonfatal
MI, in patients with hyperlipidemia undergoing CABG
urgery. However, preoperative statin therapy is not asso-
iated with reduced in-hospital mortality compared with
hat seen in statin-untreated hyperlipidemic or normolipi-
emic patients. Conversely, the present study also demon-
trates that statin-untreated normolipidemic patients are not
t any short-term increased risk, either for in-hospital mor-
ality or for MACEs, compared with statin-treated hyperlip-
demic patients. Finally, preoperative statin therapy does not
eem to be superior in terms of reduced early mortality and
ACE rate compared with values seen in statin-untreated
ormolipidemic patients, suggesting that these early beneficial
tatin effects predominantly seem to be due to their lipid-
owering properties.
Numerous clinical trials have demonstrated that decreas-
ng LDL-C levels is highly effective in primary and sec-
ndary prevention of CAD by substantially reducing the
isk of adverse cardiovascular events, particularly in se-
ected groups of patients with hyperlipidemia,2 familial
therosclerosis,14 a previous history of CABG,15,16 or acute
ABLE 4. Univariate and multivariate logistic regression a
Univariate an
Odds ratio (95% CI)
ge, y 1.01 (1.00–1.03)
ex, female 1.13 (0.81–1.57)
besity 1.10 (0.81–1.53)
eft main stem disease 0.93 (0.67–1.28)
VEF, % 0.98 (0.97–0.99)
eripheral vascular disease 1.65 (1.16–2.35)
OPD 1.69 (1.21–2.37)
iabetes mellitus 1.31 (0.97–1.77)
ypertension 1.60 (0.96–2.67)
ngina CCS III-IV 1.57 (1.11–2.21)
revious MI 1.63 (1.22–2.19)
enal disease 1.70 (1.18–2.45)
spirin 0.83 (0.62–1.13)
-Blockers 0.78 (0.59–1.04)
o. of bypassed vessels 1.29 (1.09–1.54)
roup 1: statin-untreated HLP Reference
roup 2: statin-treated HLP 0.42 (0.26–0.69)
roup 3: statin-untreated NLP 0.31 (0.17–0.57)
ACE, Major adverse cardiac event; CI, confidence interval; LVEF, left ve
anadian Cardiovascular Society; HLP, hyperlipidemia; NLP, normolipidemoronary syndromes17 or during coronary interventions,18 t
148 The Journal of Thoracic and Cardiovascular Surgery ● Novut favorable statin effects are also seen, irrespective of
aseline LDL-C levels and the presence or absence of other
ardiac risk factors.19 There is also evidence that corona
laque’s inflammatory characteristics strongly influence the
ikelihood of plaque rupture, which is at highest risk in
yperlipidemic patients. Plaque rupture occurs either spon-
aneously or as a result of coronary manipulation (by means
f percutaneous coronary intervention or CABG surgery),
ausing microinfarctions with myocardial inflammatory re-
ponse as a result of microembolization,20 which in turn 
educed in patients undergoing statin treatment.17,20-22 In
he setting of cardiac surgery, preoperative statin therapy
as been proved effective in several recent clinical studies
y reducing the release of proinflammatory cytokines, thus
ttenuating postoperative inflammatory reactions after car-
iac surgery with cardiopulmonary bypass.23,24 Moreover,
everal recent large-scale observational cohort studies ana-
yzed whether favorable effects of preoperative statins
ight exist, irrespective of whether patients had preopera-
ively increased LDL-C levels or hyperlipidemia.6-9 How-
ver, most of the recent large-scale clinical trials analyzed the
fficacy of preoperative statin treatment by pooling those pa-
ients with increased LDL-C levels and statin-untreated hyper-
ipidemia, which is the primary target of lipid-lowering
tatin therapy, with statin-untreated normolipidemic pa-
ients and therefore failed to define the outcome in statin-
ntreated normolipidemic patients. Moreover, to date, little
s known about the potential early benefit of serum choles-
sis of variables associated with MACEs
Multivariate analysis
P value Odds ratio (95% CI) P value
.05 1.02 (0.99–1.04) .10
.49 — —
.51 — —
.65 — —
.001 0.99 (0.98–1.00) .11
.006 1.26 (0.83–1.90) .28
.002 1.33 (0.90–1.96) .16
.08 — —
.07 — —
.01 1.36 (0.92–2.01) .12
.001 1.46 (1.04–2.05) .03
.005 1.45 (0.95–2.22) .09
.23 — —
.08 — —
.004 1.32 (1.09–1.59) .005
Reference Reference Reference
.0005 0.37 (0.22–0.63) .0003
.0002 0.27 (0.14–0.53) .0001
lar ejection fraction; COPD, chronic obstructive pulmonary disease; CCS,naly
alysis
ntricuerol reduction in more defined subgroups of patients un-
ember 2007
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CDergoing CABG with hyperlipidemia and CAD undergoing
urgical intervention. The present study therefore precisely
efined the study groups, not only focusing on preoperative
tatin treatment but also considering the preoperative lipid
evels, which were not addressed in the previous statin
utcome studies performed in patients undergoing CABG
urgery.6-9 Thus we could clearly demonstrate that ea
eneficial effects of preoperative statin therapy, resulting in
significantly reduced incidence of PMI, only exist in
tatin-treated hyperlipidemic patients after CABG.
Although normolipidemic patients who did not receive
reoperative statins had no increase in MACEs in this
eries, results from other CABG studies6-9,16 and those o
atients with acute coronary syndromes25 would suggest
hat all patients undergoing CABG, irrespective of their
aseline LDL-C levels, might benefit form perioperative
nd long-term statin therapy. Although some of those pa-
ients might not exhibit immediate short-term benefits, the
resent study did not examine long-term MACEs and the
ncidence of future cardiovascular events. It is likely that
his cohort of patients will also benefit from the reduction of
ong-term MACEs by instituting perioperative statin ther-
py, despite their lower preoperative LDL-C levels.
The major limitation of the present study is its retro-
pective and nonrandomized design. Additionally, there
re several important preoperative group differences in
linical characteristics and risk factors, as well as in the
nequal study group size itself. Furthermore, statin-un-
reated hyperlipidemic patients might well be identified
s a surrogate for patients receiving “substandard preop-
rative medical care” and therefore be vulnerable to other
ntreated maladies. We therefore accounted for these
ifferences by means of careful statistical adjustment,
sing multivariate risk-adjusted and propensity score–
djusted regression models. In addition, the small sample
ize of statin-untreated patients during the observation
eriod of more than 6 years indicates today’s widespread
nd highly established use of statins. Furthermore, the
ffect of precise preoperative statin therapy, considering
he dose and duration, before CABG was not analyzed
nd should be addressed in future studies.
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